公开(公告)号：US20240343830A1

公开(公告)日：2024-10-17

申请号：US18628104

申请日：2024-04-05

Applicant: Omeros Corporation ,  University of Leicester

Inventor： Gregory A. Demopulos ,  Thomas A. Dudler ,  Hans-Wilhelm Schwaeble

IPC: C07K16/40 ,  A61K39/00 ,  A61P7/02 ,  A61P37/02

CPC classification number: C07K16/40 ,  A61P7/02 ,  A61P37/02 ,  C12Y304/21104 ,  A61K2039/505 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

公开(公告)号：US20240294669A1

公开(公告)日：2024-09-05

申请号：US18666945

申请日：2024-05-17

Applicant: Anthos Therapeutics, Inc.

Inventor： Debra A. FREEDHOLM ,  Daniel M. BLOOMFIELD ,  Royston J. GLASSPOOL ,  Jonathan E. FREEMAN ,  Yasser KHDER

IPC: C07K16/36 ,  A61K39/00 ,  A61K47/22 ,  A61K47/26 ,  A61P7/02

CPC classification number: C07K16/36 ,  A61K47/22 ,  A61K47/26 ,  A61P7/02 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/76

Abstract: This disclosure relates to dosage regimens for anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies or antigen-binding fragments thereof, pharmaceutical formulations comprising the same, and pharmaceutical formulations for use in the treatment of thromboembolic disorders or related conditions. Also provided are pharmaceutical formulations of anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof. Also provided are methods of treating patients having thrombocytopenias with anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof.

公开(公告)号：US20240285674A1

公开(公告)日：2024-08-29

申请号：US18577953

申请日：2022-07-04

Applicant: NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Jianfa ZHANG ,  Qian LIN ,  Lei WANG

IPC: A61K31/737 ,  A61P7/02 ,  C08B37/00

CPC classification number: A61K31/737 ,  A61P7/02 ,  C08B37/006

Abstract: The present invention relates to the field of anticoagulant and antithrombotic drugs, and in particular to an application of sulfate gluco-galacto-oligosaccharide in preparation of an anticoagulant and/or antithrombotic drug. Disclosed in the present invention is the application of sulfate gluco-galacto-oligosaccharide in the preparation of the anticoagulant and/or antithrombotic drug. The structural formula of sulfate gluco-galacto-oligosaccharide is that R1-R24 are independently SO3− or H, but not all H. Sulfate gluco-galacto-oligosaccharide of the present invention has obvious anticoagulant activity in vivo and in vitro, and can be used for preparing the anticoagulant and/or antithrombotic drug.

公开(公告)号：US20240285581A1

公开(公告)日：2024-08-29

申请号：US18629099

申请日：2024-04-08

Applicant: Boulder BioScience LLC

Inventor： Michael A. Zeligs ,  Irwin C. Jacobs

IPC: A61K31/404 ,  A61K9/00 ,  A61K31/122 ,  A61K31/137 ,  A61K31/203 ,  A61K31/23 ,  A61K31/4045 ,  A61K31/41 ,  A61K31/4427 ,  A61K31/451 ,  A61K31/4706 ,  A61K31/51 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/704 ,  A61K38/46 ,  A61K38/48 ,  A61K39/395 ,  A61P7/02 ,  A61P9/10

CPC classification number: A61K31/404 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/122 ,  A61K31/137 ,  A61K31/203 ,  A61K31/23 ,  A61K31/4045 ,  A61K31/41 ,  A61K31/4427 ,  A61K31/451 ,  A61K31/4706 ,  A61K31/51 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/704 ,  A61K38/465 ,  A61K38/482 ,  A61K39/3955 ,  A61P7/02 ,  A61P9/10

Abstract: Provided herein are methods of enhancing mechanical thrombectomy during endovascular therapy for acute thrombosis using 3,3′-diindolylmethane.

公开(公告)号：US20240277640A1

公开(公告)日：2024-08-22

申请号：US18615533

申请日：2024-03-25

Applicant: Abrexa Pharmaceuticals, Inc.

Inventor： Jesus E. VILLAFRANCA ,  Charles Richard KISSINGER

IPC: A61K31/167 ,  A61K31/4365 ,  A61K31/616 ,  A61K31/7064 ,  A61K31/727 ,  A61K38/48 ,  A61P7/02

CPC classification number: A61K31/167 ,  A61K31/4365 ,  A61K31/616 ,  A61K31/7064 ,  A61K31/727 ,  A61K38/482 ,  A61P7/02

Abstract: Presented herein are compositions and methods for preventing, reducing, delaying and treating a coronavirus infection and related disorders such as respiratory distress, disseminated intravascular coagulation, and central nervous system pathologies caused by coronavirus infection.

公开(公告)号：US20240238272A1

公开(公告)日：2024-07-18

申请号：US18561712

申请日：2022-06-01

Applicant: Genovate Biotechnology Co. Ltd.

Inventor： Jen Chen ,  Chia-Chen Chu

IPC: A61K31/4706 ,  A61P7/02

CPC classification number: A61K31/4706 ,  A61P7/02

Abstract: A method for treating antiphospholipid syndrome by administering to a patient a pharmaceutical composition that contains S-(+)-hydroxychloroquine and a pharmaceutically acceptable excipient. The pharmaceutical composition is substantially free of R-(−)-hydroxychloroquine.

公开(公告)号：US20240156906A1

公开(公告)日：2024-05-16

申请号：US18394080

申请日：2023-12-22

Applicant: BIOXODES

Inventor： Valérie PIREAUX ,  Stéphanie DEMOULIN ,  Edmond GODFROID ,  Joël TASSIGNON ,  Sandrine DEROCHETTE ,  Michel GUYAUX

IPC: A61K38/17 ,  A61P7/02

CPC classification number: A61K38/1767 ,  A61P7/02

Abstract: Disclosed is an Ixodes ricinus salivary gland polypeptide and its use for inhibiting the extrinsic coagulation pathway and for treating and/or preventing diseases and conditions, such as thrombotic events, associated with the recruitment and activation of neutrophils following activation of the extrinsic coagulation pathway.

公开(公告)号：US20240141068A1

公开(公告)日：2024-05-02

申请号：US17983349

申请日：2022-11-08

Applicant: Kai Yuan Xu

Inventor： Kai Yuan Xu

IPC: C07K16/40 ,  A61K38/16 ,  A61K39/00 ,  A61K39/395 ,  A61P7/02 ,  C07K16/00 ,  C12N9/14

CPC classification number: C07K16/40 ,  A61K38/16 ,  A61K39/0005 ,  A61K39/395 ,  A61K39/3955 ,  A61P7/02 ,  C07K16/00 ,  C12N9/14 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/76

Abstract: Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

公开(公告)号：US20240131098A1

公开(公告)日：2024-04-25

申请号：US18173316

申请日：2023-02-23

Applicant: Andong National University Industry-Academic Cooperation Foundation

Inventor： Ho Yong SOHN

IPC: A61K36/074 ,  A23L31/00 ,  A61P7/02 ,  C12N1/14

CPC classification number: A61K36/074 ,  A23L31/00 ,  A61P7/02 ,  C12N1/14

Abstract: Proposed are pharmaceutical compositions and health functional foods containing a Ganoderma lucidum fruiting body extract as an active ingredient for preventing, treating, or ameliorating thrombosis. The extract exhibits strong antithrombotic activity by inhibiting thrombosis-related enzymes and blood coagulation factors, has excellent thermal stability, and exhibits no loss of blood coagulation factor inhibitory effect and thrombogenic enzyme inhibitory effect even in acidic conditions of pH 2 and in plasma. Therefore, the Ganoderma lucidum fruiting body extract is expected to be used for the prevention and treatment of thrombosis, which causes ischemic stroke and hemorrhagic stroke, by improving blood circulation. The Ganoderma lucidum fruiting body extract is very useful in the pharmaceutical and food industries.

公开(公告)号：US11964004B2

公开(公告)日：2024-04-23

申请号：US17709403

申请日：2022-03-30

Applicant: SHENZHEN BAY LABORATORY

Inventor： Xinli Henry Lin

IPC: A61K38/48 ,  A61P7/02

CPC classification number: A61K38/484 ,  A61P7/02

Abstract: The present disclosure provides is a short in vivo half-life and in vivo unstable recombinant microplasmin, wherein the recombinant microplasmin can be a mutant type and wild type and is expressed in a bacteria host, can be purified, or can be refolded and purified in case expressed as an insoluble inclusion body, producing an active thrombolytic agent. The present disclosure also provides the pharmaceutical composition comprising the recombinant microplasmin and method of treating thromboembolism related diseases including the administration of the pharmaceutical composition.